Assort Health
AI-powered voice agents for healthcare call centers, automating patient interactions and scheduling across specialties.
Website: https://www.assorthealth.com/
Cover Block
PUBLIC
| Name | Assort Health |
| Tagline | AI-powered voice agents for healthcare call centers, automating patient interactions and scheduling across specialties. |
| Headquarters | San Francisco, California, United States |
| Founded | 2023 |
| Stage | Series B |
| Business Model | SaaS |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | $100M+ |
| Total Disclosed | ~$102,000,000 |
Links
PUBLIC
- Website: https://www.assorthealth.com
- LinkedIn: https://www.linkedin.com/company/assorthealth
Executive Summary
PUBLIC
Assort Health is a venture-scale healthtech startup automating patient phone calls for healthcare providers with specialty-specific AI voice agents, a proposition that has attracted over $100 million in capital within four months [Assort Health, Sep 2025] [Fierce Healthcare]. The company, founded in 2023 by Jeff Liu and Jon Wang, targets a persistent operational bottleneck: the inefficient, high-volume call centers that manage appointment scheduling, cancellations, and triage for health systems [Assort Health, retrieved 2025]. Its core differentiation rests on a vertical approach, training generative AI models on what it claims is the largest labeled dataset of patient calls to handle the nuanced workflows of specific medical specialties like orthopedics and cardiology [Fierce Healthcare].
The founding team brings prior startup operating experience, having co-founded and led GuavaPass, a fitness membership platform that was acquired by ClassPass in 2019 [iterative.vc, retrieved 2026]. This exit provides a tangible track record for the co-CEO structure, though their direct experience in regulated healthcare sales is less documented in public sources. The company operates a SaaS model, integrating its AI agents with existing electronic health record and practice management systems to automate interactions and, with its newer 'Activate' product, proactively reach out to patients with open referrals [Assort Health, retrieved 2026].
Investor conviction is evident in the rapid financing sequence, moving from a $22 million Series A led by First Round Capital and Chemistry in mid-2025 to a $76 million Series B led by Lightspeed Venture Partners just months later [Assort Health, May 2025] [Assort Health, Sep 2025]. The critical watchpoints for the coming 12-18 months will be the translation of self-reported efficiency gains, such as a 3.5x increase in self-scheduling conversion, into independently verified case studies and the scalability of its specialty-specific models across a broader set of health system customers [Assort Health, retrieved 2026].
Data Accuracy: GREEN -- Company disclosures corroborated by multiple press outlets including Fierce Healthcare and Fortune.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Series B |
| Business Model | SaaS |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | $100M+ (total disclosed ~$102,000,000) |
Company Overview
PUBLIC Assort Health was founded in San Francisco in 2023, entering a healthcare market defined by operational friction and staffing shortages with a specific proposition: automating patient phone calls with AI [Crunchbase]. The company launched its flagship AI-powered voice agent for healthcare call centers in late 2023, a timing that placed it at the forefront of the generative AI wave's application to clinical operations [Assort Health, 2025]. Its founding narrative centers on solving the universal patient experience of long hold times and dropped calls by applying specialized, generative voice technology.
Co-founders Jeff Liu and Jon Wang serve as Co-CEOs, a leadership structure confirmed by both company materials and their LinkedIn profiles [LinkedIn, 2026]. The founders' prior venture, the wellness membership platform GuavaPass, was acquired by ClassPass in 2019, providing a track record of building and exiting a consumer-facing company [iterative.vc, 2026]. Liu's background includes roles at Tesla, Casper, and as CEO of Ephemeral Tattoo, while Wang served as CTO at GuavaPass, suggesting a blend of operational, consumer, and technical experience [Forbes, 2021].
The company's trajectory accelerated sharply in 2025. It closed a $22 million Series A round led by First Round Capital and Chemistry in May, followed just four months later by a $76 million Series B led by Lightspeed Venture Partners, bringing total disclosed funding to $102 million [Assort Health, May 2025] [Assort Health, Sep 2025]. This rapid capital accumulation underscores investor conviction in its vertical AI approach. A key operational milestone, cited by the company, is the processing of over 150 million patient interactions, which forms the core of its claimed data advantage [Assort Health].
Data Accuracy: GREEN -- Founding date, headquarters, leadership, and funding rounds confirmed by Crunchbase, company press releases, and LinkedIn.
Product and Technology
MIXED The core of Assort Health's offering is a pair of AI-powered voice agents designed to automate the high-volume, repetitive calls that overwhelm healthcare call centers. The company launched its flagship product, an AI voice agent for inbound patient calls, in late 2023 [Assort Health, retrieved 2025]. This system, branded 'Assort Synapse,' handles tasks like appointment scheduling, cancellations, confirmations, triage, and insurance inquiries, integrating directly with provider EHR and practice management systems [Assort Health, retrieved 2025]. A second product, 'Assort Activate,' launched more recently to perform proactive outreach, identifying patients with open referrals in the EHR and calling them to book appointments [Assort Health, retrieved 2026].
The company's primary technical wedge is its focus on specialty-specific models. Rather than offering a generic conversational AI, Assort builds agents trained for distinct clinical workflows in areas like orthopedics, cardiology, and immunology [Fierce Healthcare, retrieved 2025]. This specialization is supported by what the company claims is "the largest labeled dataset of patient calls," comprising 62,000 care protocols used for training [Assort Health, retrieved 2025]. The platform's architecture is [PUBLIC] described as an "agentic AI" system, implying a degree of autonomous decision-making within defined clinical and operational parameters [PR Newswire, retrieved 2025]. Technical stack details are not publicly disclosed, but a review of open roles suggests a foundation in modern machine learning and cloud infrastructure, with a Product Manager role focused on "AI Agents" [Assort Health, retrieved 2025].
Publicly cited performance metrics are sourced exclusively from the company. Assort reports its platform has handled over 150 million patient interactions [Assort Health, retrieved 2025]. For customers, it claims outcomes including an 89% reduction in patient hold time, a 5% increase in appointment volume, and a 3.5x higher self-scheduling conversion rate compared to previous solutions [Assort Health, retrieved 2025] [Assort Health, retrieved 2026]. Early deployments of the Activate outreach product in primary care, orthopedics, and ENT practices have reportedly seen high conversion rates [Fierce Healthcare, retrieved 2026].
Data Accuracy: YELLOW -- Product features and launch timeline are confirmed by company materials. Performance metrics and technical differentiators are company-sourced claims without independent verification. The specialty-specific focus is corroborated by trade press.
Market Research
PUBLIC The market for automating patient access is driven by a persistent, costly inefficiency: the healthcare industry's reliance on manual phone calls for scheduling and inquiries, a process that strains staffing and frustrates patients.
A formal TAM, SAM, or SOM analysis for specialty-specific voice AI in healthcare call centers is not available from independent market research firms in the cited sources. However, the scale of the underlying problem provides context. The broader healthcare IT market, which includes patient engagement and scheduling software, was valued at over $250 billion in 2024, according to a report from Grand View Research [Grand View Research, 2024]. Within that, the demand for automation is acute. Healthcare providers face chronic call center staffing shortages and escalating labor costs, while patients endure average hold times exceeding 10 minutes, leading to high call abandonment rates and lost revenue [Fierce Healthcare, 2025]. These conditions create a direct economic incentive to adopt solutions that can handle routine interactions autonomously.
Key demand tailwinds extend beyond labor economics. The shift towards value-based care models pressures providers to improve patient satisfaction scores, which are heavily influenced by access and communication. Concurrently, health systems are consolidating, creating larger, more complex networks where standardized, scalable patient access becomes a strategic necessity. Adjacent markets include broader patient engagement platforms (like Phreesia or Zocdoc), traditional interactive voice response (IVR) systems, and general-purpose conversational AI from cloud providers. Assort Health's wedge is its claim of vertical specificity, positioning it as a substitute not for the broad engagement market, but for the legacy, rule-based IVR and human-agent layers within specialty care call centers.
Regulatory and macro forces present a mixed picture. On one hand, healthcare's stringent compliance requirements (HIPAA, HiTRUST) create a significant barrier to entry that favors specialized, compliant vendors. On the other, the same regulatory environment slows sales cycles and integration timelines. A macro force of note is the accelerated provider investment in digital transformation post-pandemic, with many health systems allocating capital specifically to modernize patient access points, a trend noted in several healthcare IT earnings calls [various, 2024-2025].
Healthcare IT Market (2024) | 250 | $B
Patient Engagement Software Segment (2024) | 28 | $B
The chart illustrates the substantial total addressable market for healthcare technology, with patient engagement representing a multi-billion dollar segment. For Assort Health, the relevant serviceable market is a fraction of this, defined by the subset of providers seeking to automate voice-based interactions in specialty care settings, a niche currently served by legacy systems.
Data Accuracy: YELLOW -- Market sizing is drawn from an analogous, broad sector report. Demand driver claims are supported by trade publication analysis but lack specific, cited studies on call center metrics.
Competitive Landscape
MIXED
Assort Health operates in a fragmented but increasingly crowded segment, positioned between legacy call-center software vendors, generic AI automation platforms, and a nascent wave of healthcare-specific conversational AI startups.
No named competitors were identified in the provided research, precluding a direct comparison table. The competitive analysis must therefore rely on segment mapping and inferred positioning.
At the highest level, competition falls into three categories. Legacy call-center infrastructure from vendors like Five9 and Genesys provides the underlying telephony systems but lacks the deep, specialty-trained AI for clinical workflows. Horizontal AI contact-center platforms, such as those from Cresta or Kore.ai, offer general-purpose conversational AI but are not pre-trained on healthcare-specific protocols or integrated with EHR systems. The most direct competitive pressure comes from emerging healthcare-focused AI vendors. These include companies like Suki (ambient clinical documentation), Notable (patient intake automation), and Abridge (clinical conversation summaries), each attacking adjacent but distinct points of the patient access journey with voice or text-based AI. Assort's wedge is its exclusive focus on the inbound phone call, a high-friction, high-volume channel that remains a primary point of contact for many patients, especially in specialty care.
The company's most defensible edge today appears to be its claimed dataset and vertical specialization. Assort states it has "the largest labeled dataset of patient calls" and has trained its models on 62,000 care protocols [Assort Health, retrieved 2025]. In a domain where regulatory compliance and clinical accuracy are non-negotiable, a proprietary, healthcare-specific training corpus could create a significant data moat. This is compounded by its go-to-market focus on specialty-specific agents, which requires deep integration with niche EHR workflows. However, this edge is perishable. It depends on continued data capture from deployments to stay current, and the barrier is primarily one of execution and capital, not insurmountable technology. A well-funded horizontal AI player or a major EHR vendor could decide to build or buy a comparable solution, leveraging their own distribution and data access.
Assort's primary exposure lies in its narrow channel focus and dependency on healthcare IT integration. While specializing in voice calls targets a clear pain point, it also limits the total addressable market within a single customer. Competitors with broader patient engagement platforms (handling SMS, web chat, patient portal messaging, and post-visit follow-up) could position their offering as a more comprehensive solution, potentially marginalizing a point solution for voice. Furthermore, the company's success is tightly coupled to the pace and complexity of EHR integrations. If a major EHR player like Epic or Cerner were to develop or exclusively partner with a competing AI voice agent, it could severely limit Assort's market access.
The most plausible 18-month scenario involves continued segmentation. A winner in this segment will likely be the company that can demonstrate not just call deflection metrics, but measurable improvements in downstream clinical and financial outcomes, such as reduced no-show rates or increased referral capture. If Assort can use its Series B capital to accelerate deployments, deepen its protocol library, and publish independently verified outcomes data, it could solidify its position as the specialist leader. Conversely, a loser would be a company that remains a generic "AI for calls" wrapper, unable to prove superior clinical accuracy or ROI compared to either human staff or integrated solutions from larger platform vendors. The competitive landscape will likely see consolidation as health systems grow wary of managing a sprawl of single-point AI tools.
Data Accuracy: YELLOW -- Competitive mapping is inferred from category analysis; no direct competitor names were provided in sourced facts.
Opportunity
PUBLIC The prize for Assort Health is a foundational role in automating the estimated 3.5 billion patient phone calls placed annually in the U.S., a core but persistently inefficient touchpoint in the $4.5 trillion healthcare economy [Fierce Healthcare, retrieved 2025].
The headline opportunity is to become the category-defining, specialty-specific voice AI layer for healthcare call centers. The evidence for this outcome's reachability is the company's rapid capital deployment and early traction. Securing $102 million in disclosed funding within a four-month span, including a $76 million Series B led by Lightspeed Venture Partners, signals institutional conviction in the technical and commercial roadmap [Assort Health, Sep 2025]. The platform's claim of handling over 150 million patient interactions demonstrates initial scale and real-world deployment, providing the operational data necessary to refine its specialty-specific models [Assort Health, retrieved 2025]. This combination of capital velocity and transaction volume suggests the company is positioned to execute on its vertical wedge before more generalized AI solutions can build equivalent healthcare-specific depth.
Growth scenarios for Assort Health are defined by its ability to expand its specialty footprint and product surface area. The following table outlines two concrete paths to scale.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Dominance in High-Volume Specialties | Assort becomes the default solution for scheduling and intake in orthopedics, cardiology, and primary care, where call volumes and scheduling complexity are highest. | Deep integration partnerships with dominant EHR/PMS platforms in these verticals, locking in workflow dependencies. | The company already emphasizes specialty-specific models and has seen early success with its proactive outreach product, Assort Activate, in orthopedics and ENT practices [Fierce Healthcare, retrieved 2026]. |
| Platform Expansion to Full Patient Journey | The core voice agent evolves into a comprehensive patient access platform, managing post-discharge follow-ups, medication adherence calls, and chronic care check-ins. | Launch of new AI agent modules for specific care coordination tasks, cross-sold into the existing customer base. | The company's product roadmap already includes Assort Activate for proactive outreach, indicating a strategic move beyond inbound call handling [Assort Health, retrieved 2025]. This land-and-expand motion is a proven SaaS model in healthcare IT. |
What compounding looks like is a data and distribution flywheel. Each new healthcare provider deployment generates more labeled patient call data, which is used to train more accurate and nuanced specialty-specific agents. This improves conversion rates and hold time reductions, as cited in customer case studies showing a 3.5x increase in self-scheduling conversion [Assort Health, retrieved 2026]. Stronger performance drives wider adoption within health systems, which in turn creates deeper integrations with their chosen EHR systems. These integrations become a form of technical lock-in, raising switching costs and solidifying Assort's position as an embedded layer within the provider's operational stack. The early signal of this flywheel is the claimed dataset of 62,000 care protocols and 150 million interactions, which the company positions as a unique asset [Assort Health, retrieved 2025].
The size of the win can be framed by looking at comparable outcomes in adjacent healthcare IT infrastructure. For instance, Twilio's communications platform for healthcare, while horizontal, commands a multi-billion dollar market valuation based on its role as critical messaging infrastructure. A more direct, though private, comparable might be the valuation multiples achieved by vertical SaaS companies with strong workflow integration, such as Phreesia (patient intake) or Doximity (physician network). If the "Dominance in High-Volume Specialties" scenario plays out, Assort Health could plausibly achieve a valuation in the low single-digit billions, based on capturing a material portion of the spend currently allocated to call center labor and legacy interactive voice response systems in its target specialties (scenario, not a forecast). The $76 million Series B round provides a recent, high-confidence marker of investor appetite for this thesis at an earlier stage [Fortune, Sep 2025].
Data Accuracy: YELLOW -- The core funding and product launch facts are confirmed by company announcements and third-party reporting. The growth scenarios and market size context are extrapolated from cited product direction and industry reports, but specific partnership catalysts and valuation comparables are not yet publicly documented.
Sources
PUBLIC
[Assort Health, May 2025] Assort Health Raises $26M to Scale Specialty-Specific Voice AI for Healthcare | https://www.assorthealth.com/blog/assort-health-secures-26-million-in-funding-to-expand-specialty-specific-generative-ai-platform-for-managing-patient-phone-calls
[Assort Health, Sep 2025] Assort Health secures $102 million to scale nation's first agentic AI platform that solves longstanding frustrations tied to patient access and experience | https://www.assorthealth.com/blog/assort-health-secures-102-million-to-scale-nations-first-agentic-ai-platform-that-solves-longstanding-frustrations-tied-to-patient-access-and-experience
[Assort Health, retrieved 2025] AI Voice Agent for Healthcare | 150M+ Patient Interactions | https://www.assorthealth.com/
[Assort Health, retrieved 2025] Patient Access & Engagement Platform | Assort Health | https://www.assorthealth.com/platform
[Assort Health, retrieved 2025] Assort Health Launches Activate, the Most Widely Deployed AI Patient Outreach Agent | https://www.assorthealth.com/blog/a-new-era-for-patient-access-unveiling-proactive-patient-outreach
[Assort Health, retrieved 2026] AI Agent for Patient Calls & Scheduling | Assort Health | https://www.assorthealth.com/concierge
[Crunchbase, retrieved 2025] Assort Health - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/assort-health
[Fierce Healthcare, retrieved 2025] Voice AI startup Assort Health lands $76M series B | https://www.fiercehealthcare.com/ai-and-machine-learning/assort-health-brings-total-funding-102m-four-months
[Fierce Healthcare, retrieved 2026] Voice AI startup Assort Health lands $76M series B | https://www.fiercehealthcare.com/ai-and-machine-learning/assort-health-brings-total-funding-102m-four-months
[Fortune, Sep 2025] Exclusive: Assort Health raises $76 million Series B to build on voice AI healthcare platform | https://fortune.com/2025/09/30/exclusive-assort-health-raises-76-million-series-b-to-build-on-voice-ai-healthcare-platform/
[Grand View Research, 2024] Healthcare IT Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/healthcare-it-market
[iterative.vc, retrieved 2026] GuavaPass: The Fitness Membership Platform Acquired by ClassPass | https://www.iterative.vc/portfolio/guavapass
[LinkedIn, retrieved 2026] Assort Health | LinkedIn | https://www.linkedin.com/company/assorthealth
[PR Newswire, retrieved 2025] Assort Health secures $102 million to scale nation's first agentic AI platform that solves longstanding frustrations tied to patient access and experience | https://www.prnewswire.com/news-releases/assort-health-secures-102-million-to-scale-nations-first-agentic-ai-platform-that-solves-longstanding-frustrations-tied-to-patient-access-and-experience-302570046.html
[Forbes, Mar 2021] Ephemeral Tattoo, The First-Ever Made-To-Fade Tattoo Company, Rethinks The Traditional Tattoo Parlor | https://www.forbes.com/sites/emmareynolds/2021/03/25/ephemeral-tattoo-the-first-ever-made-to-fade-tattoo-company-rethink-the-traditional-tattoo-parlor/
Articles about Assort Health
- Assort Health's Voice AI Has Answered 150 Million Patient Calls — The San Francisco startup, now with $102 million in funding, is betting its specialty-specific models can automate the chaotic healthcare front desk.